Lista de obras - Lionel Adès - Dominio Público Uruguay

A landscape of germline mutations in a cohort of inherited bone marrow failure patients

artículo científico publicado en 2017

A multiparametric niche-like drug screening platform in acute myeloid leukemia

artículo científico publicado en 2022

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure

artículo científico publicado en 2019

A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome

scientific article published on 01 July 2019

Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine

artículo científico publicado en 2012

An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia

artículo científico publicado en 2016

Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?

artículo científico publicado en 2016

Auer rods and differentiation in acute promyelocytic leukemia

Azacitidine in untreated acute myeloid leukemia: a report on 149 patients

artículo científico publicado en 2014

BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia

artículo científico publicado en 2017

Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia

artículo científico publicado en 2015

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.

artículo científico publicado en 2017

Clonal architecture of chronic myelomonocytic leukemias

artículo científico publicado en 2013

Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy

artículo científico publicado en 2020

Comparison of TP53 mutations screening by functional assay of separated allele in yeast and next-generation sequencing in myelodysplastic syndromes

artículo científico publicado en 2015

DNA topoisomerase II in therapy-related acute promyelocytic leukemia.

artículo científico publicado en 2005

Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia.

artículo científico publicado en 2018

Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy.

artículo científico publicado en 2004

Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison

artículo científico publicado en 2008

Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia.

artículo científico publicado en 2011

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study

artículo científico publicado en 2007

Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group.

artículo científico publicado en 2015

Exome analysis of treatment-related AML after APL suggests secondary evolution

scientific article published on 22 November 2018

Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia

artículo científico publicado en 2018

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

artículo científico publicado en 2021

Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia

scholarly article by Ashfaq Ali et al published 26 February 2018 in Leukemia

Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia

artículo científico publicado en 2011

Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine

artículo científico publicado en 2017

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

artículo científico publicado en 2020

Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group

article by Lionel Adès et al published 20 December 2006 in Journal of Clinical Oncology

Letter to the Editor: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality

scientific article published on 30 July 2020

Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD.

artículo científico publicado en 2012

Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes

artículo científico publicado en 2012

Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients

artículo científico publicado en 2013

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

scientific article published on 01 January 2020

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.

artículo científico publicado en 2011

Myelodysplastic syndromes

artículo científico publicado en 2014

Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group.

artículo científico publicado en 2012

Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.

artículo científico publicado en 2015

Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine

artículo científico publicado en 2013

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.

artículo científico publicado en 2018

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

artículo científico publicado en 2010

Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study

artículo científico publicado en 2013

Prognostic score including gene mutations in chronic myelomonocytic leukemia.

artículo científico publicado en 2013

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine

artículo científico publicado en 2014

Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis

artículo científico publicado en 2013

Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents

scientific article published on 03 December 2019

Slow relapse in acute myeloid leukemia with inv(16) or t(16;16).

artículo científico publicado en 2009

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial

artículo científico publicado en 2018

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

scientific article published on 11 January 2019

Tc1 clonal T cell expansion during chronic graft-versus-host disease-associated hypereosinophilia

artículo científico publicado en 2014

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience

artículo científico publicado en 2012

Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine

artículo científico publicado en 2012

Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).

artículo científico publicado en 2010

Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience

artículo científico publicado en 2009

When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group).

artículo científico publicado en 2009

mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents

scholarly article by Pedro Henrique Prata et al published October 2018 in Haematologica

Lista de obras de Lionel Adès

A landscape of germline mutations in a cohort of inherited bone marrow failure patients

A multiparametric niche-like drug screening platform in acute myeloid leukemia

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure

A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome

Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine

An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia

Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?

Auer rods and differentiation in acute promyelocytic leukemia

Azacitidine in untreated acute myeloid leukemia: a report on 149 patients

BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia

Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.

Clonal architecture of chronic myelomonocytic leukemias

Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy

Comparison of TP53 mutations screening by functional assay of separated allele in yeast and next-generation sequencing in myelodysplastic syndromes

DNA topoisomerase II in therapy-related acute promyelocytic leukemia.

Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia.

Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy.

Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison

Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia.

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study

Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group.

Exome analysis of treatment-related AML after APL suggests secondary evolution

Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia

Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia

Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group

Letter to the Editor: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality

Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD.

Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes

Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.

Myelodysplastic syndromes

Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group.

Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.

Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study

Prognostic score including gene mutations in chronic myelomonocytic leukemia.

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine

Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis

Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents

Slow relapse in acute myeloid leukemia with inv(16) or t(16;16).

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

Tc1 clonal T cell expansion during chronic graft-versus-host disease-associated hypereosinophilia

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience

Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine

Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).

Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience

When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group).

mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents